Company Overview
Aptevo Therapeutics Inc. operates as a clinical-stage research and development biotechnology entity dedicated to the United States market, where it develops immunotherapeutic candidates aimed at treating various forms of cancer. The company functions within the broader healthcare sector, specifically specializing in the biotechnology industry, which implies a focus on high-risk, high-reward scientific innovation and product development cycles. In terms of scale, the organization maintains a market capitalization of $6.67M while employing a workforce of 37 individuals to support its R&D initiatives. The combination of a market cap of $6.67M and annual revenue that is currently N/A indicates that Aptevo Therapeutics is a micro-cap entity with limited financial scale, suggesting it is in an early-stage development phase where capital allocation is primarily directed toward clinical trials rather than commercial sales operations.
Financial Health
The company reports N/A for revenue over the trailing twelve months, a net income of $-27,952,000, and an EBITDA of $-26,468,000, highlighting a significant gap between top-line activity and profitability that reveals a cost structure dominated by heavy research and development expenditures. With a free cash flow of $-16,131,250, the company is currently burning cash, which indicates that its financial flexibility is constrained and dependent on external capital raising or existing cash reserves to fund operations. The analysis of margins shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, which collectively indicate that the company has not yet achieved commercial profitability and that all revenue generated, if any, is insufficient to cover operating costs or generate net income. On the balance sheet, Aptevo holds $21.06M in cash against $4.79M in debt, resulting in a debt-to-equity ratio of 27.54, which suggests a leveraged position where the company relies significantly on equity financing rather than debt obligations to fund its activities. Despite the debt presence, the current ratio stands at 4.03, indicating strong short-term liquidity as the company possesses ample current assets relative to its current liabilities to meet obligations within the next year. Return metrics reveal a return on equity of -242.7% and a return on assets of -79.2%, which demonstrates that management has not yet generated positive returns on the capital invested or deployed, a common characteristic for clinical-stage biotechs but one that signals ongoing financial pressure.
Valuation Assessment
The valuation metrics display a trailing P/E ratio of N/A and a forward P/E of -0.23, implying that the difference between these figures stems from the absence of current earnings and the negative earnings projection expected in the near term. The price-to-book ratio is recorded at 0.19, indicating that the market values the company at a fraction of its book value, which typically suggests that the market prices the stock based on its intangible asset potential rather than tangible book value, or that the company faces significant valuation discounts due to its development stage. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and an EV/EBITDA of 0.46, suggest that traditional multiples are not applicable due to lack of sales, while the low EV/EBITDA reflects the negative earnings profile. Regarding price volatility, the stock has seen a 52-week high of $1299.60 and a 52-week low of $3.95, meaning the current trading price sits at 100% below the 52-week high if referenced against the low, or specifically, the price range spans nearly 329 times from low to high. The beta value is 1.43, which explains that the stock's price volatility is 43% higher than the broader market, indicating that price movements will likely be more extreme than standard market indices.
Growth & Income
The company reports N/A for revenue growth year-over-year and N/A for earnings growth year-over-year, which implies that historical growth rates cannot be calculated due to the lack of established commercial revenue streams or consistent earnings history. As a non-dividend payer, Aptevo Therapeutics does not offer a dividend yield or a payout ratio, which means the company reinvests all available earnings, or rather its limited capital, into research and development growth rather than distributing income to shareholders. The overall growth and income profile is characterized by a total absence of current revenue generation and dividend distributions, focusing entirely on the capital-intensive process of bringing immunotherapeutic candidates to market.